NCT00722176View on ClinicalTrials.gov

Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

PHASE2CompletedINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

December 31, 2009

Conditions

Schizophrenia

Interventions

DRUG

BL-1020

10 mg

DRUG

BL-1020 10-30 mg

BL-1020 10-30 mg

DRUG

risperidone

risperidone

Trial Locations (1)

92868

University of California, Irvine, Irvine

Sponsors

Lead Sponsor

BioLineRx, Ltd.

All Listed Sponsors

lead

BioLineRx, Ltd.

INDUSTRY

NCT00722176 - Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 | Biotech Hunter | Biotech Hunter